Ideaya Biosciences Inc (IDYA)

$37.93 +1.39 (3.80%)
Market Cap 3.21B
Revenue (ttm) 218.71M
Net Income (ttm) -113.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -51.99%
Debt to Equity Ratio 0.00
Volume 629,400
Avg Vol 1,142,570
Day's Range N/A - N/A
Shares Out 87.86M
Stochastic %K 98%
Beta -0.10
Analysts Strong Sell
Price Target $51.28

Company Profile

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also o...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 443 6209
Address:
5000 Shoreline Court, Suite 300, South San Francisco, United States
SannieVerraderlijk
SannieVerraderlijk Aug. 19 at 10:25 AM
$IDYA Let them cook https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-clinical-collaboration-with-genentech-in-mtap-deleted-kras-g12d-mutant-pancreatic-cancer-302854505.html
1 · Reply
CDMO
CDMO Aug. 18 at 8:28 PM
$IDYA $VRDN very strong today
1 · Reply
Valueforall
Valueforall Aug. 18 at 2:54 PM
$IDYA A goo man says here nothing to see here all normal. When high-conviction synthetic lethality leaders get pinned in chop, low volatility is the ultimate test of patience. Give us an algorithmic tape shakeout to $32–$33 so we can load the truck before the next clinical catalyst leg up
1 · Reply
CH_Expat
CH_Expat Aug. 18 at 6:02 AM
$IDYA $MLYS $VERA Those three stocks underperformed XBI by more than 50% YTD. Interesting.
4 · Reply
CH_Expat
CH_Expat Aug. 17 at 7:45 AM
$VERA $IDYA $MLYS Always encouraging to see in the 13Fs that the biotech All-Star-Funds bought more of your holdings for higher prices than you did. Not the one parameter to watch, but gives you a good feeling anyway.
1 · Reply
CH_Expat
CH_Expat Aug. 16 at 8:40 PM
$IDYA Baker Bros added more than one million shares in Q2. Guess my surprise.
1 · Reply
vjtweet
vjtweet Aug. 13 at 6:58 PM
$IDYA setting up. Has order in place.
0 · Reply
CapitalMonk
CapitalMonk Aug. 13 at 4:18 PM
$IDYA Price: $36.91 (-0.13%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±0.68% RSI: 61.3 | Momentum: Moderate Volume: -74.9% vs avg Volatility: 1.93% Support: $34.01 | Resistance: $37.90 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
0 · Reply
CH_Expat
CH_Expat Aug. 12 at 5:44 PM
$IDYA The fake algo hungergames are in full bloom here. Volume dead. This can a take a few weeks, but not forever. South or North we go and soon.
1 · Reply
vu_jade
vu_jade Aug. 11 at 1:46 AM
$IDYA great looking entry area
0 · Reply
Latest News on IDYA
Ideaya Biosciences enters IDE892 collaboration with Genentech

2026-08-19T10:10:54.000Z - 3 hours ago

Ideaya Biosciences enters IDE892 collaboration with Genentech

IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

Aug 19, 2026, 6:00 AM EDT - 3 hours ago

IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

Ideaya Biosciences price target lowered to $42 from $45 at Citizens

2026-08-06T19:35:59.000Z - 12 days ago

Ideaya Biosciences price target lowered to $42 from $45 at Citizens

Ideaya Biosciences price target raised to $60 from $58 at Wedbush

2026-08-05T14:29:09.000Z - 13 days ago

Ideaya Biosciences price target raised to $60 from $58 at Wedbush

Ideaya Biosciences price target lowered to $59 from $63 at Truist

2026-08-05T14:07:32.000Z - 13 days ago

Ideaya Biosciences price target lowered to $59 from $63 at Truist

Ideaya Biosciences reports Q2 EPS ($1.22), consensus ($1.05)

2026-08-04T11:36:19.000Z - 15 days ago

Ideaya Biosciences reports Q2 EPS ($1.22), consensus ($1.05)

IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 4, 2026, 6:00 AM EDT - 15 days ago

IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

IDEAYA Biosciences Earnings release: Q2 2026

Aug 4, 2026, 6:00 AM EDT - 15 days ago

IDEAYA Biosciences Earnings release: Q2 2026

IDEAYA Biosciences Quarterly report: Q2 2026

Aug 4, 2026, 6:00 AM EDT - 15 days ago

IDEAYA Biosciences Quarterly report: Q2 2026

IDEAYA Biosciences Slides: Corporate presentation

Aug 3, 2026, 9:00 AM EDT - 16 days ago

IDEAYA Biosciences Slides: Corporate presentation

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jul 31, 2026, 6:00 AM EDT - 19 days ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Ideaya Biosciences initiates monotherapy expansion in IDE892 trial

2026-07-27T10:11:39.000Z - 23 days ago

Ideaya Biosciences initiates monotherapy expansion in IDE892 trial

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

Jul 27, 2026, 6:00 AM EDT - 23 days ago

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

Jul 17, 2026, 9:00 AM EDT - 4 weeks ago

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

Ideaya Biosciences price target lowered to $63 from $65 at Truist

2026-07-07T13:15:30.000Z - 6 weeks ago

Ideaya Biosciences price target lowered to $63 from $65 at Truist

Ideaya Biosciences price target lowered to $48 from $53 at RBC Capital

2026-07-07T11:35:59.000Z - 6 weeks ago

Ideaya Biosciences price target lowered to $48 from $53 at RBC Capital

Ideaya Biosciences elects CEO Yujiro Hata as chairman

2026-06-17T10:35:07.000Z - 2 months ago

Ideaya Biosciences elects CEO Yujiro Hata as chairman

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

Jun 17, 2026, 6:00 AM EDT - 2 months ago

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

Ideaya Biosciences enrolls first patient in IDE892 trial

2026-06-15T10:05:59.000Z - 2 months ago

Ideaya Biosciences enrolls first patient in IDE892 trial

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

Jun 15, 2026, 6:00 AM EDT - 2 months ago

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

IDEAYA Biosciences Slides: Corporate presentation

Jun 12, 2026, 9:00 AM EDT - 2 months ago

IDEAYA Biosciences Slides: Corporate presentation

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jun 10, 2026, 4:05 PM EDT - 2 months ago

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Ideaya Biosciences 5.56M share Spot Secondary priced at $27.00

2026-06-09T10:15:20.000Z - 2 months ago

Ideaya Biosciences 5.56M share Spot Secondary priced at $27.00

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

Jun 8, 2026, 10:22 PM EDT - 2 months ago

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

Ideaya Biosciences $300M Spot Secondary re-offered at $27.00

2026-06-08T20:13:05.000Z - 2 months ago

Ideaya Biosciences $300M Spot Secondary re-offered at $27.00

Ideaya Biosciences announces $300M common stock offering

2026-06-08T20:05:34.000Z - 2 months ago

Ideaya Biosciences announces $300M common stock offering

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jun 8, 2026, 4:01 PM EDT - 2 months ago

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

IDEAYA Biosciences Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 7:35 AM EDT - 2 months ago

IDEAYA Biosciences Transcript: Jefferies Global Healthcare Conference 2026

Ideaya Biosciences announces IDE892 collaboration with Roche

2026-06-03T10:09:39.000Z - 2 months ago

Ideaya Biosciences announces IDE892 collaboration with Roche

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

Jun 3, 2026, 6:00 AM EDT - 2 months ago

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

Ideaya Biosciences, Servier present data from Phase 2/3 OptimUM-02 trial

2026-06-01T15:26:27.000Z - 2 months ago

Ideaya Biosciences, Servier present data from Phase 2/3 OptimUM-02 trial

IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO

Jun 1, 2026, 11:00 AM EDT - 2 months ago

IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO

Ideaya Biosciences management to meet with Cantor

2026-05-26T20:55:08.000Z - 3 months ago

Ideaya Biosciences management to meet with Cantor

IDEAYA Biosciences Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 26, 2026, 11:00 AM EDT - 3 months ago

IDEAYA Biosciences Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference

May 26, 2026, 6:00 AM EDT - 3 months ago

IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference

IDEAYA Biosciences Transcript: Stifel 2026 Targeted Oncology Virtual Forum

May 19, 2026, 12:00 PM EDT - 3 months ago

IDEAYA Biosciences Transcript: Stifel 2026 Targeted Oncology Virtual Forum

IDEAYA Biosciences Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 8:00 PM EDT - 3 months ago

IDEAYA Biosciences Transcript: Bank of America Global Healthcare Conference 2026

Ideaya Biosciences price target lowered to $50 from $52 at Mizuho

2026-05-07T15:52:20.000Z - 3 months ago

Ideaya Biosciences price target lowered to $50 from $52 at Mizuho

IDEAYA Biosciences Slides: Corporate presentation

May 5, 2026, 7:00 AM EDT - 3 months ago

IDEAYA Biosciences Slides: Corporate presentation

Ideaya Biosciences reports Q1 EPS ($1.11), consensus (98c)

2026-05-05T10:23:24.000Z - 3 months ago

Ideaya Biosciences reports Q1 EPS ($1.11), consensus (98c)

IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

May 5, 2026, 6:00 AM EDT - 3 months ago

IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

IDEAYA Biosciences Earnings release: Q1 2026

May 5, 2026, 6:00 AM EDT - 3 months ago

IDEAYA Biosciences Earnings release: Q1 2026

IDEAYA Biosciences Quarterly report: Q1 2026

May 5, 2026, 6:00 AM EDT - 3 months ago

IDEAYA Biosciences Quarterly report: Q1 2026

IDEAYA Biosciences Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

IDEAYA Biosciences Proxy statement: Proxy filing

Ideaya Biosciences announces darovasertib combination NDA to be reviewed by FDA

2026-04-30T10:37:31.000Z - 3 months ago

Ideaya Biosciences announces darovasertib combination NDA to be reviewed by FDA

IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program

Apr 30, 2026, 6:00 AM EDT - 3 months ago

IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program

IDEAYA Biosciences Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

IDEAYA Biosciences Proxy statement: Proxy filing

IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma

Apr 21, 2026, 10:15 AM EDT - 4 months ago

IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma

IDEAYA Biosciences Transcript: Study result

Apr 13, 2026, 8:00 AM EDT - 4 months ago

IDEAYA Biosciences Transcript: Study result

IDEAYA Biosciences Press release: Study result

Apr 13, 2026, 8:00 AM EDT - 4 months ago

IDEAYA Biosciences Press release: Study result

IDEAYA Biosciences Slides: Study result

Apr 13, 2026, 8:00 AM EDT - 4 months ago

IDEAYA Biosciences Slides: Study result

Ideaya Biosciences Stock Jumps 15% on Eye Cancer Therapy Trial Results

Apr 13, 2026, 7:21 AM EDT - 4 months ago

Ideaya Biosciences Stock Jumps 15% on Eye Cancer Therapy Trial Results

IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma

Apr 13, 2026, 6:00 AM EDT - 4 months ago

IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma

IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026

Apr 10, 2026, 4:05 PM EDT - 4 months ago

IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer

Apr 6, 2026, 6:00 AM EDT - 4 months ago

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma

Mar 30, 2026, 6:00 AM EDT - 5 months ago

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma

IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial

Mar 22, 2026, 10:00 AM EDT - 5 months ago

IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial

IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs

Mar 18, 2026, 6:00 AM EDT - 5 months ago

IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs

IDEAYA Biosciences Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 5 months ago

IDEAYA Biosciences Slides: Corporate presentation

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update

Mar 9, 2026, 6:00 AM EDT - 5 months ago

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034

Feb 27, 2026, 7:00 PM EST - 6 months ago

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC

Feb 25, 2026, 6:00 AM EST - 6 months ago

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC

IDEAYA Biosciences Transcript: Status update

Feb 23, 2026, 12:00 PM EST - 6 months ago

IDEAYA Biosciences Transcript: Status update

IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer

Feb 23, 2026, 6:00 AM EST - 6 months ago

IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer

IDEAYA Biosciences Transcript: Citi’s 2026 Virtual Oncology Leadership Summit

Feb 18, 2026, 1:00 PM EST - 6 months ago

IDEAYA Biosciences Transcript: Citi’s 2026 Virtual Oncology Leadership Summit

IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Feb 17, 2026, 6:00 AM EST - 6 months ago

IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

IDEAYA Biosciences Annual report: Q4 2025

Feb 17, 2026, 6:00 AM EST - 6 months ago

IDEAYA Biosciences Annual report: Q4 2025

IDEAYA Biosciences Earnings release: Q4 2025

Feb 17, 2026, 6:00 AM EST - 6 months ago

IDEAYA Biosciences Earnings release: Q4 2025

IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events

Feb 2, 2026, 6:00 AM EST - 7 months ago

IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events

IDEAYA Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 PM EST - 7 months ago

IDEAYA Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

IDEAYA Biosciences Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 PM EST - 7 months ago

IDEAYA Biosciences Slides: 44th Annual J.P. Morgan Healthcare Conference

IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 12:00 PM EST - 7 months ago

IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference

IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 6:00 AM EST - 8 months ago

IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference

IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma

Dec 11, 2025, 6:00 AM EST - 8 months ago

IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma

IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers

Dec 10, 2025, 6:00 AM EST - 9 months ago

IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance

Dec 4, 2025, 7:00 PM EST - 9 months ago

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance

IDEAYA Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 10:50 AM EST - 9 months ago

IDEAYA Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

IDEAYA Biosciences Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 9:00 AM EST - 9 months ago

IDEAYA Biosciences Transcript: Citi Annual Global Healthcare Conference 2025

IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types

Dec 1, 2025, 6:00 AM EST - 9 months ago

IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types

IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events

Nov 24, 2025, 6:00 AM EST - 9 months ago

IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events

IDEAYA Biosciences Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 8:00 AM EST - 9 months ago

IDEAYA Biosciences Transcript: Jefferies London Healthcare Conference 2025

IDEAYA Biosciences Transcript: Citi's 2025 SMID Cap Biopharma Call Series

Nov 6, 2025, 12:00 PM EST - 10 months ago

IDEAYA Biosciences Transcript: Citi's 2025 SMID Cap Biopharma Call Series

IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 6:00 AM EST - 10 months ago

IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

IDEAYA Biosciences Quarterly report: Q3 2025

Nov 4, 2025, 6:00 AM EST - 10 months ago

IDEAYA Biosciences Quarterly report: Q3 2025

IDEAYA Biosciences Earnings release: Q3 2025

Nov 4, 2025, 6:00 AM EST - 10 months ago

IDEAYA Biosciences Earnings release: Q3 2025

IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events

Oct 27, 2025, 6:00 AM EDT - 10 months ago

IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025

Oct 20, 2025, 6:30 AM EDT - 10 months ago

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025

IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

Oct 20, 2025, 6:00 AM EDT - 10 months ago

IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer

Sep 8, 2025, 8:00 AM EDT - 1 year ago

IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer

IDEAYA Biosciences Transcript: R&D Day 2025

Sep 8, 2025, 8:00 AM EDT - 1 year ago

IDEAYA Biosciences Transcript: R&D Day 2025

IDEAYA Biosciences Slides: FY 2025

Sep 8, 2025, 8:00 AM EDT - 1 year ago

IDEAYA Biosciences Slides: FY 2025

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma

Sep 8, 2025, 6:00 AM EDT - 1 year ago

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma

IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer

Sep 7, 2025, 12:00 PM EDT - 1 year ago

IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer

IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer

Sep 4, 2025, 6:00 AM EDT - 1 year ago

IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer

IDEAYA Biosciences Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 9:10 AM EDT - 1 year ago

IDEAYA Biosciences Transcript: Cantor Global Healthcare Conference 2025

IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors

Sep 3, 2025, 6:00 AM EDT - 1 year ago

IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide

Sep 2, 2025, 6:00 AM EDT - 1 year ago

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide

IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

Aug 29, 2025, 2:00 PM EDT - 1 year ago

IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events

Aug 25, 2025, 6:00 AM EDT - 1 year ago

IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events

IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025

Aug 18, 2025, 6:00 AM EDT - 1 year ago

IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025

IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 6:00 AM EDT - 1 year ago

IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

IDEAYA Biosciences Quarterly report: Q2 2025

Aug 5, 2025, 6:00 AM EDT - 1 year ago

IDEAYA Biosciences Quarterly report: Q2 2025

IDEAYA Biosciences Earnings release: Q2 2025

Aug 5, 2025, 6:00 AM EDT - 1 year ago

IDEAYA Biosciences Earnings release: Q2 2025

SannieVerraderlijk
SannieVerraderlijk Aug. 19 at 10:25 AM
$IDYA Let them cook https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-clinical-collaboration-with-genentech-in-mtap-deleted-kras-g12d-mutant-pancreatic-cancer-302854505.html
1 · Reply
CDMO
CDMO Aug. 18 at 8:28 PM
$IDYA $VRDN very strong today
1 · Reply
Valueforall
Valueforall Aug. 18 at 2:54 PM
$IDYA A goo man says here nothing to see here all normal. When high-conviction synthetic lethality leaders get pinned in chop, low volatility is the ultimate test of patience. Give us an algorithmic tape shakeout to $32–$33 so we can load the truck before the next clinical catalyst leg up
1 · Reply
CH_Expat
CH_Expat Aug. 18 at 6:02 AM
$IDYA $MLYS $VERA Those three stocks underperformed XBI by more than 50% YTD. Interesting.
4 · Reply
CH_Expat
CH_Expat Aug. 17 at 7:45 AM
$VERA $IDYA $MLYS Always encouraging to see in the 13Fs that the biotech All-Star-Funds bought more of your holdings for higher prices than you did. Not the one parameter to watch, but gives you a good feeling anyway.
1 · Reply
CH_Expat
CH_Expat Aug. 16 at 8:40 PM
$IDYA Baker Bros added more than one million shares in Q2. Guess my surprise.
1 · Reply
vjtweet
vjtweet Aug. 13 at 6:58 PM
$IDYA setting up. Has order in place.
0 · Reply
CapitalMonk
CapitalMonk Aug. 13 at 4:18 PM
$IDYA Price: $36.91 (-0.13%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±0.68% RSI: 61.3 | Momentum: Moderate Volume: -74.9% vs avg Volatility: 1.93% Support: $34.01 | Resistance: $37.90 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
0 · Reply
CH_Expat
CH_Expat Aug. 12 at 5:44 PM
$IDYA The fake algo hungergames are in full bloom here. Volume dead. This can a take a few weeks, but not forever. South or North we go and soon.
1 · Reply
vu_jade
vu_jade Aug. 11 at 1:46 AM
$IDYA great looking entry area
0 · Reply
CH_Expat
CH_Expat Aug. 7 at 11:43 AM
$IDYA •2H26: Complete NDA filing for darovasertib in uveal melanoma •2H26: Initiate combo IDE892 with RG6505 (panRAS) •2H26: Clinical update for darovasertib in HLA-A2 positive patients at ESMO •2H26: Clinical update for darovasertib in neoadjuvant primary UM (OptimUM-09 trial) at ESMO •2H26: Hengrui update for IDE849 (DLL3 ADC) at ESMO •4Q26: R&D day •2H26: IDE849 Ph1/2 US clinical update •2H26: IDE034 Ph1/2 clinical update I expect great result after great result and a stock price of 2b EV.
2 · Reply
CH_Expat
CH_Expat Aug. 6 at 1:46 PM
$IDYA Fake anchor zone to make you bail.
0 · Reply
DasBrinkus
DasBrinkus Aug. 4 at 12:01 PM
$IDYA https://www.prnewswire.com/news-releases/ideaya-biosciences-reports-second-quarter-2026-financial-results-and-provides-business-update-302841723.html
0 · Reply
DasBrinkus
DasBrinkus Jul. 27 at 8:03 PM
$IDYA Credit to @RonIsWrong https://ir.ideayabio.com/2026-07-27-IDEAYA-Biosciences-Announces-IDE892,-a-Potential-Best-in-Class-MTA-Cooperative-PRMT5-Inhibitor,-Initiates-Part-2-Monotherapy-Expansion-in-the-Phase-1-2-Study-in-MTAP-Deleted-Pancreatic-and-Lung-Cancers
0 · Reply
Merlintrader
Merlintrader Jul. 27 at 4:24 PM
$IDYA IDEAYA Biosciences: the darovasertib approval trade — and the pipeline the market may still be underpricing https://www.merlintrader.com/ideaya-biosciences-stock-hub/
0 · Reply
STACKD0E
STACKD0E Jul. 27 at 11:02 AM
$PFSA $NCTY $IDYA $SVCO ✨️
0 · Reply
CH_Expat
CH_Expat Jul. 24 at 4:03 PM
$IDYA Very unusual stock price behavior since the opening bell. Just saying. Probably to myself only.
2 · Reply
kkun
kkun Jul. 23 at 7:42 PM
$IDYA ready for the next leg up!!
0 · Reply
CH_Expat
CH_Expat Jul. 23 at 11:08 AM
$IDYA Adding zone 28-30. $MLYS Adding zone 23-24 Candidates at lower prices: CLDX, TRVI, NRIX, IVA, SNDX, KURA Candidates at much lower prices: COGT, CELC Horror-All-Star-Trash-Team: ALT, SLS, TNXP, CADL, CAPR
4 · Reply
CH_Expat
CH_Expat Jul. 20 at 1:51 PM
$IDYA At this levels, not even all indiciations for Daro are priced in. None is 892, 849 and 034. Not to mention the others. Boreout range here before the magic begins. Yujiro leading BOD also tells me he wants clean track to sell in 2027 or 2028. If CRNX can go for 10b, IDYA can do the same.
1 · Reply
kkun
kkun Jul. 20 at 2:38 AM
$IDYA ready for the next leg up!!
0 · Reply
Merlintrader
Merlintrader Jul. 17 at 5:49 PM
$IDYA IDEAYA Biosciences: the darovasertib approval trade — and the pipeline the market may still be underpricing https://www.merlintrader.com/ideaya-biosciences-stock-hub/
0 · Reply